Obinutuzumab

Obinutuzumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-Hodgkin Lymphoma、Burkitt Lymphoma、Diffuse Large B-Cell Lymphoma、Primary Mediastinal B-cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Obinutuzumab 研究

• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  II 期招募中美国NCT03516617

• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

  II 期招募中美国Brazil加拿大法国NCT05039619

• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  II 期招募中美国澳大利亚加拿大法国NCT06806033

• A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

  不适用招募中中国NCT05899621

• Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

  II 期招募中中国NCT07299149

• A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

  I 期 / II 期招募中美国澳大利亚Brazil中国NCT05533775

• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  III 期招募中美国澳大利亚法国GreeceNCT06428019

• Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF

  III 期招募中法国NCT04702256

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  II 期招募中美国NCT06649812

• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  III 期招募中美国澳大利亚Brazil加拿大NCT06084936

• Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas

  II 期招募中RussiaNCT07883135

• MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

  II 期招募中中国NCT06793189

• A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

  I 期 / II 期招募中美国澳大利亚Brazil中国NCT06634589

• Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome

  II 期 / III 期招募中法国NCT05786768

• Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

  II 期招募中中国NCT06513234

• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

  II 期招募中中国NCT06094881

• Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

  不适用招募中中国NCT07126678

• MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

  II 期招募中法国Poland西班牙英国NCT06534437

• Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

  II 期招募中意大利NCT04908228

• Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

  I 期 / II 期招募中美国NCT07520006

• Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

  IV 期招募中中国NCT07355699

• A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab

  II 期招募中法国NCT07268521

• Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

  II 期招募中英国NCT05848765

• A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

  I 期招募中中国香港日本中国台湾NCT07107490

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。